RecallCheckr

Moderate recall: A hazard has been identified, with no injuries reported yet. Follow the steps below.

Genentech Inc 2022-11-09 Health moderate FDA
Health · FDA · Recall #FDA-D-0025-2023

Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One… Recall

Issued November 9, 2022 · Genentech Inc

In November 2022, Genentech Inc recalled the Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One…, a moderate health recall reported by the FDA.

Compiled by Maya Ellison, RecallCheckr

What this means for you

Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.

What you should do

  1. 1 Stop using Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One… right away.
  2. 2 Set it aside where it won't be used by mistake.
  3. 3 Contact Genentech Inc to arrange your voluntary. See the official notice below for contact details.
  4. 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):

Recall details

Brand
Genentech Inc
Category
Health
Recall date
November 9, 2022
Units affected
Not reported
Sold at
Nationwide in the USA
Recall number
FDA-D-0025-2023
Made in
United States
Issuing agency
FDA

In context

  • Genentech Inc has 1 recall in our database.
  • We're tracking 3,576 Health recalls in our database.
  • This is the 870th Health recall we've logged in 2022.
Read the official FDA notice

Related recalls